Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of the oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors (SYLVER)

    Cancer Categories
    • Gastrointestinal (GI),Gynecologic
    Karmanos Trial ID
    • 2024-092
    NCT ID
    • NCT06710847
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I/II
    Principal Investigator

    Objective:

    Part 1: Monotherapy Dose Escalation

    Primary Objectives:

    • Determine the Maximum Tolerated Dose and/or RDE for GSK4418959 as monotherapy (MTD and/or RDE).
    • Assess safety and tolerability of GSK4418959 as monotherapy within the DLT observation period.

    Secondary Objectives:

    • Characterize the PK properties of GSK4418959, as monotherapy
    • Further assess the safety and tolerability of GSK4418959 as monotherapy, within and outside of the DLT observation period.

    Part 2: Monotherapy Dose Expansion

    Primary Objectives:

    • Evaluate the preliminary anti-tumor activity of GSK4418959 in CRC and, separately, in EC.

    Secondary Objectives:

    • Further evaluate the safety of GSK4418959 administered at the RDE for CRC and/or for EC.
    • Further evaluate the anti-tumor activity of GSK4418959 in CRC and separately, in EC.
    • Characterize the PK properties of GSK4418959.

    Part 3: Combination Dose Escalation

    Primary Objectives:

    • Determine the Maximum Tolerated Dose and/or RDE for GSK4418959 in combination with dostarlimab (MTDc and/or RDEc).
    • Assess safety and tolerability of GSK4418959 in combination with dostarlimab within the DLT observation period.

    Secondary Objectives:

    • Characterize the PK properties of GSK4418959, in combination with dostarlimab.
    • Further assess the safety and tolerability of GSK4418959 in combination with dostarlimab, within and outside of the DLT observation period.
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions